United BioSource Corporation (UBC)
announced the acquisition of
Abt Bio-Pharma Solutions, Inc.
(ABS), a Boston, Massachusetts-based provider of health economics and outcomes research, registries and observational studies, and market access solutions to the biopharmaceutical, medical device, and diagnostics industries.
The acquisition of ABS is part of UBC’s ongoing strategy to build a “best in class” portfolio of scientific and medical affairs solutions to support biopharmaceutical and medical technology companies. With this acquisition UBC further expands its team of senior experts in comparative effectiveness and comparative value; increases its registry and observational study practices; and reinforces its commercial strategy and market access capabilities.
“UBC is an ideal home for ABS,” said Abt Associates Chief Executive Officer Kathleen Flanagan. “We are gratified to see our colleagues join an organization that shares our values. At UBC, there will be new resources and increased reach that translates into new opportunities for our clients to support the development and commercialization of their products.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.